BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38369762)

  • 21. Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence.
    Li T; Qiu T; Zeng Y; Kang B; Tang X; Yang N; Xiao H
    Evid Based Complement Alternat Med; 2022; 2022():3321099. PubMed ID: 36045654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
    Spanheimer PM; Cyr AR; Gillum MP; Woodfield GW; Askeland RW; Weigel RJ
    Ann Surg; 2014 Apr; 259(4):793-9. PubMed ID: 24045439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
    Zhou Y; Inaba S; Liu J
    Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dependency of Tamoxifen Sensitive and Resistant ER
    Bhasin S; Dusek C; Peacock JW; Cherkasov A; Wang Y; Gleave M; Ong CJ
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
    Srirangam A; Mitra R; Wang M; Gorski JC; Badve S; Baldridge L; Hamilton J; Kishimoto H; Hawes J; Li L; Orschell CM; Srour EF; Blum JS; Donner D; Sledge GW; Nakshatri H; Potter DA
    Clin Cancer Res; 2006 Mar; 12(6):1883-96. PubMed ID: 16551874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
    Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
    Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
    Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
    Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA
    Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
    Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
    J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
    Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
    J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
    Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
    Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-regulation of LRP16 mRNA by 17beta-estradiol through activation of estrogen receptor alpha (ERalpha), but not ERbeta, and promotion of human breast cancer MCF-7 cell proliferation: a preliminary report.
    Han WD; Mu YM; Lu XC; Xu ZM; Li XJ; Yu L; Song HJ; Li M; Lu JM; Zhao YL; Pan CY
    Endocr Relat Cancer; 2003 Jun; 10(2):217-24. PubMed ID: 12790785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
    Al-Dhfyan A; Alhoshani A; Korashy HM
    Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway.
    Liang W; Shi J; Xia H; Wei X
    Oxid Med Cell Longev; 2021; 2021():5537737. PubMed ID: 34221232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2.
    Tan S; Ding K; Li R; Zhang W; Li G; Kong X; Qian P; Lobie PE; Zhu T
    Breast Cancer Res; 2014 Apr; 16(2):R40. PubMed ID: 24735615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
    Bhowmik T; Gomes A
    Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SNCG shRNA suppressed breast cancer cell xenograft formation and growth in nude mice.
    Shen PH; Fan QX; Li YW; Zhang W; He XK; Wang Z; Zhang YH
    Chin Med J (Engl); 2011 May; 124(10):1524-8. PubMed ID: 21740810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.